These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Current and Emerging Perspectives on Immunotherapy for Melanoma. Daud A Semin Oncol; 2015 Dec; 42 Suppl 3():S3-S11. PubMed ID: 26598057 [TBL] [Abstract][Full Text] [Related]
12. Melanoma drug wins US approval. Ledford H Nature; 2011 Mar; 471(7340):561. PubMed ID: 21455150 [No Abstract] [Full Text] [Related]
13. Aflibercept, ipilimumab, and vemurafenib. Hussar DA; Au AY J Am Pharm Assoc (2003); 2012; 52(2):291-4. PubMed ID: 22370387 [No Abstract] [Full Text] [Related]
14. How should we use anti-CTLA-4 antibodies? Marabelle A; Eggermont A Eur J Cancer; 2015 Nov; 51(17):2686-8. PubMed ID: 26613660 [No Abstract] [Full Text] [Related]
15. Facing the dawn of immunotherapy for hepatocellular carcinoma. Sprinzl MF; Galle PR J Hepatol; 2013 Jul; 59(1):9-10. PubMed ID: 23571018 [No Abstract] [Full Text] [Related]
17. Future directions for checkpoint inhibition in melanoma. Hamid O Clin Adv Hematol Oncol; 2016 Feb; 14(2):85-6. PubMed ID: 27057805 [No Abstract] [Full Text] [Related]
18. Immune checkpoint blockade in patients with melanoma metastatic to the brain. Di Giacomo AM; Margolin K Semin Oncol; 2015 Jun; 42(3):459-65. PubMed ID: 25965364 [TBL] [Abstract][Full Text] [Related]
19. [When CRAF takes over BRAF in melanoma]. Dumaz N; Bagot M; Bensussan A Med Sci (Paris); 2011 Oct; 27(10):817-9. PubMed ID: 22027417 [No Abstract] [Full Text] [Related]
20. Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy. Felix J; Cassinat B; Porcher R; Schlageter MH; Maubec E; Pages C; Baroudjian B; Homyrda L; Boukouaci W; Tamouza R; Bagot M; Caignard A; Toubert A; Lebbé C; Moins-Teisserenc H Int Immunopharmacol; 2016 Nov; 40():466-473. PubMed ID: 27728898 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]